Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma”

Regarding “Yttrium-90 Radioembolization for Unresectable Combined... Cardiovasc Intervent Radiol (2017) 40:1479 DOI 10.1007/s00270-017-1707-0 LETTE R T O T HE EDI T OR Regarding ‘‘Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma’’ Zhongzhi Jia Received: 22 April 2017 / Accepted: 19 May 2017 / Published online: 26 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 We read with great interest the recent article by Chan et al. may bias the results. Secondly, there were a total of 3 [1]. The authors concluded that radioembolization with patients with macrovascular invasion according to Table 1, yttrium-90 microspheres appears to be a promising treat- but there were 4 patients with macrovascular invasion ment option for patients with unresectable combined hep- according to Figure 2B, which causes serious confusion to atocellular–cholangiocarcinoma, and poor performance the readers. status and the presence of macrovascular invasion were Compliance with Ethical Standards identified as predictors of reduced survival after radioem- bolization. However, we would like to elaborate on the Conflicts of interest The author declares that he has no competing treatments pre- and post-radioembolization of the patients. interests. Firstly, there were a total of 10 patients included in this study, and many of them had received wide-ranging ther- apies pre- and post-radioembolization, including References chemotherapy, hepatectomy, and TACE. In particular, patients 7 and 10 had chemorefractory hepatocellular– 1. Chan LS, Sze DY, Poultsides GA, et al. Yttrium-90 radioem- cholangiocarcinoma with macrovascular invasion, and both bolization for unresectable combined hepatocellular–cholangio- of them had not received any treatment after radioem- carcinoma. Cardiovasc Intervent Radiol. 2017. doi:10.1007/ bolization even though with stable disease, all of which s00270-017-1648-7. & Zhongzhi Jia jiazhongzhi.1998@163.com Department of Interventional Radiology, No. 2 People’s Hospital of Changzhou, Nanjing Medical University, Xing Long Road 29#, Changzhou 213003, China http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma”

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/regarding-yttrium-90-radioembolization-for-unresectable-combined-WFN9Yo1RuO
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
D.O.I.
10.1007/s00270-017-1707-0
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol (2017) 40:1479 DOI 10.1007/s00270-017-1707-0 LETTE R T O T HE EDI T OR Regarding ‘‘Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma’’ Zhongzhi Jia Received: 22 April 2017 / Accepted: 19 May 2017 / Published online: 26 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 We read with great interest the recent article by Chan et al. may bias the results. Secondly, there were a total of 3 [1]. The authors concluded that radioembolization with patients with macrovascular invasion according to Table 1, yttrium-90 microspheres appears to be a promising treat- but there were 4 patients with macrovascular invasion ment option for patients with unresectable combined hep- according to Figure 2B, which causes serious confusion to atocellular–cholangiocarcinoma, and poor performance the readers. status and the presence of macrovascular invasion were Compliance with Ethical Standards identified as predictors of reduced survival after radioem- bolization. However, we would like to elaborate on the Conflicts of interest The author declares that he has no competing treatments pre- and post-radioembolization of the patients. interests. Firstly, there were a total of 10 patients included in this study, and many of them had received wide-ranging ther- apies pre- and post-radioembolization, including References chemotherapy, hepatectomy, and TACE. In particular, patients 7 and 10 had chemorefractory hepatocellular– 1. Chan LS, Sze DY, Poultsides GA, et al. Yttrium-90 radioem- cholangiocarcinoma with macrovascular invasion, and both bolization for unresectable combined hepatocellular–cholangio- of them had not received any treatment after radioem- carcinoma. Cardiovasc Intervent Radiol. 2017. doi:10.1007/ bolization even though with stable disease, all of which s00270-017-1648-7. & Zhongzhi Jia jiazhongzhi.1998@163.com Department of Interventional Radiology, No. 2 People’s Hospital of Changzhou, Nanjing Medical University, Xing Long Road 29#, Changzhou 213003, China

Journal

CardioVascular and Interventional RadiologySpringer Journals

Published: May 26, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off